Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07424287 | A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC | recruiting | Phase 3 | 236 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC(FORTIFI-HN01) | recruiting | Phase 2 / Phase 3 | 650 | Bicara TherapeuticsINDUSTRY |
| 26 |
| Jul 17, 2026 |
| clinicaltrials |
| NCT06796803 | Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) | recruiting | Phase 2 / Phase 3 | 398 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07149649 | Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 / Phase 3 | 230 | Swiss Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07487896 | A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy | recruiting | Phase 3 | 440 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07554456 | A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) | recruiting | Phase 2 / Phase 3 | 90 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07706985 | Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 566 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07705243 | Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 86 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06686771 | Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer(CURB2) | recruiting | Phase 3 | 320 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT07416474 | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | recruiting | Phase 3 | 574 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07092566 | R.E.C.K vs Exparel in Robotic Nephrectomy | recruiting | Phase 3 | 170 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07692152 | Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma | recruiting | Phase 3 | 350 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07518147 | A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment | recruiting | Phase 3 | 438 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05581121 | PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer(PAROLA) | recruiting | Phase 3 | 510 | Institut Claudius RegaudOTHER | 4 | Jul 7, 2026 | clinicaltrials |
| NCT06994195 | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) | recruiting | Phase 3 | 450 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06927986 | Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） | recruiting | Phase 3 | 380 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC(CRITⅡ) | recruiting | Phase 3 | 204 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07673029 | A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | recruiting | Phase 3 | 228 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT07131319 | SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC | recruiting | Phase 2 / Phase 3 | 30 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07385703 | Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 3 | 752 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07660094 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)(LuTK03) | recruiting | Phase 3 | 500 | Candel Therapeutics, Inc.INDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06625034 | Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer | recruiting | Phase 3 | 108 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07473128 | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | recruiting | Phase 3 | 120 | Pharmacosmos A/SINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07416994 | Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 3 | 440 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06763328 | Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy | recruiting | Phase 3 | 80 | City of Hope Medical CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05593458 | Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1(TACTIC) | recruiting | Phase 3 | 190 | Zhejiang UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | recruiting | Phase 3 | 718 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07518173 | A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 596 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07590024 | RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma(RAIRI-NPC) | recruiting | Phase 3 | 651 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | recruiting | Phase 3 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | May 22, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07594340 | HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) | recruiting | Phase 3 | 300 | Binkui LiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07264075 | Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN(ILLUMINE) | recruiting | Phase 3 | 780 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | recruiting | Phase 3 | 180 | Nuvation Bio Inc.INDUSTRY | 3 | May 19, 2026 | clinicaltrials |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 10,000 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT06431633 | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.(ARIAN) | recruiting | Phase 3 | 129 | Fundación GECPOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06277050 | Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 264 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07580300 | Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.(PRORADNOR-RCT) | recruiting | Phase 3 | 400 | Oslo University HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT06486142 | EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study(ERIS) | recruiting | Phase 3 | 200 | Region SkaneOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06437977 | Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)(neoR-TORCH) | recruiting | Phase 3 | 478 | Shanghai Chest HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07400536 | A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT | recruiting | Phase 3 | 378 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04436965 | Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition | recruiting | Phase 3 | 266 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05340491 | Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial | recruiting | Phase 3 | 212 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05941741 | IC Plus Low-dose Radiation Plus Cadonilimab in LANPC | recruiting | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 20, 2026source: clinicaltrials